Laparoscopic Roux-en-Y Gastric Bypass: Comorbidity Outcomes

E. G. Boerma; J. W.M. Greve

doi:10.1007/978-3-030-60596-4_80

Laparoscopic Roux-en-Y Gastric Bypass: Comorbidity Outcomes

E. G. Boerma^*, J. W.M. Greve

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

Abstract

Although, globally in number surpassed by the sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB) is still - by many - considered to be the golden standard in bariatric surgery with longstanding positive effects on body weight and obesity-related comorbidities. This chapter will discuss the outcomes from RYGB for comorbidity resolution (type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, gastroesophageal reflux disease, nonalcoholic fatty liver disease, and infertility) and its positive effects on cancer risk, overall mortality, quality of life, and health care costs. Throughout the chapter, these results will be compared with the other commonly used bariatric procedures.

Original language	English
Title of host publication	Obesity, Bariatric and Metabolic Surgery: A Comprehensive Guide: Second Edition
Editors	Sanjay Agrawal, Chetan Parmar
Publisher	Springer International Publishing
Pages	389-402
Number of pages	14
Edition	2
ISBN (Electronic)	9783030605964
ISBN (Print)	9783030605957
DOIs	https://doi.org/10.1007/978-3-030-60596-4_80
Publication status	Published - 1 Jan 2023

Keywords

Comorbidity
Diabetes
Gastric bypass
Metabolic syndrome
Mortality

Access to Document

10.1007/978-3-030-60596-4_80

Cite this

@inbook{260d98d80b2d4b82b90a463b39f5d4ac,

title = "Laparoscopic Roux-en-Y Gastric Bypass: Comorbidity Outcomes",

abstract = "Although, globally in number surpassed by the sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB) is still - by many - considered to be the golden standard in bariatric surgery with longstanding positive effects on body weight and obesity-related comorbidities. This chapter will discuss the outcomes from RYGB for comorbidity resolution (type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, gastroesophageal reflux disease, nonalcoholic fatty liver disease, and infertility) and its positive effects on cancer risk, overall mortality, quality of life, and health care costs. Throughout the chapter, these results will be compared with the other commonly used bariatric procedures.",

keywords = "Comorbidity, Diabetes, Gastric bypass, Metabolic syndrome, Mortality",

author = "Boerma, {E. G.} and Greve, {J. W.M.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2016, 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-030-60596-4_80",

language = "English",

isbn = "9783030605957",

pages = "389--402",

editor = "Sanjay Agrawal and Chetan Parmar",

booktitle = "Obesity, Bariatric and Metabolic Surgery: A Comprehensive Guide: Second Edition",

publisher = "Springer International Publishing",

address = "Switzerland",

edition = "2",

}

TY - CHAP

T1 - Laparoscopic Roux-en-Y Gastric Bypass

T2 - Comorbidity Outcomes

AU - Boerma, E. G.

AU - Greve, J. W.M.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2016, 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Although, globally in number surpassed by the sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB) is still - by many - considered to be the golden standard in bariatric surgery with longstanding positive effects on body weight and obesity-related comorbidities. This chapter will discuss the outcomes from RYGB for comorbidity resolution (type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, gastroesophageal reflux disease, nonalcoholic fatty liver disease, and infertility) and its positive effects on cancer risk, overall mortality, quality of life, and health care costs. Throughout the chapter, these results will be compared with the other commonly used bariatric procedures.

AB - Although, globally in number surpassed by the sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB) is still - by many - considered to be the golden standard in bariatric surgery with longstanding positive effects on body weight and obesity-related comorbidities. This chapter will discuss the outcomes from RYGB for comorbidity resolution (type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, gastroesophageal reflux disease, nonalcoholic fatty liver disease, and infertility) and its positive effects on cancer risk, overall mortality, quality of life, and health care costs. Throughout the chapter, these results will be compared with the other commonly used bariatric procedures.

KW - Comorbidity

KW - Diabetes

KW - Gastric bypass

KW - Metabolic syndrome

KW - Mortality

U2 - 10.1007/978-3-030-60596-4_80

DO - 10.1007/978-3-030-60596-4_80

M3 - Chapter

SN - 9783030605957

SP - 389

EP - 402

BT - Obesity, Bariatric and Metabolic Surgery: A Comprehensive Guide: Second Edition

A2 - Agrawal, Sanjay

A2 - Parmar, Chetan

PB - Springer International Publishing

ER -